Eli Lilly (LLY): FY25 Q1 earnings call, May 1, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s May 1, 2025 earnings call (FY25 Q1). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
16 matches for “Phase 3”; 5 quoted, at least 25 words apart.
…advanced our pipeline, invested to drive future growth and shared the first Phase 3 clinical data from our oral GLP-1 or orforglipron. Dan will share…
…millions of people around the world with chronic diseases. And we expect Phase 3 data from seven global clinical trials to read out over the…
…U.S, EU and Japan for Crohn's disease and the initiation of a Phase three program for Olomorasib in resected adjuvant non-small cell lung cancer. We…
…anticipate launches beginning in Q2. We also expect readouts from additional global Phase 3 trials later this year, which we believe will be important to…
Thanks, Lucas. I'll start with key data from our recently completed orforglipron Phase 3 trial and provide some context on our development plans and timelines…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-05-01:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-05-01:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP